US expert panel reviews how measurable residual disease is used in adult ALL
A Blood Advances article dated March 25, 2025, reviews measurable residual disease in adult ALL and notes that blinatumomab is indicated for MRD-positive B-cell ALL and, on the basis of the E1910 overall-survival result, is also used in newly diagnosed Philadelphia-negative ALL regardless of MRD response.
Blood Advances